If you have been reading about counter-ion and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
=== Stratum corneum === The stratum corneum is typically 10–20 μm thick and consists of extracellular lipid-surrounded corneocytes. The lipophilic environment of the stratum corneum can serve as a reservoir for certain highly lipophilic molecules. Keratin found in the stratum corneum may provide great affinity with certain drugs. Both of these interactions can play a role in drug accumulation in the stratum corneum and the local drug action on skin disease.
liraglutide (Victoza for type 2 diabetes, Saxenda for weight management, manufactured by Novo Nordisk), approved in 2010/2014 dulaglutide (Trulicity, manufactured by Eli Lilly), approved in 2014 semaglutide (Ozempic and Rybelsus for diabetes, Wegovy for weight management, manufactured by Novo Nordisk), approved in 2021/2019/2021 tirzepatide (a GIP analog with dual GLP-1 receptor and GIP receptor agonism; Mounjaro for diabetes, Zepbound for weight management, manufactured by Eli Lilly), approved in 2022/2024 Discontinued:
== Prognosis == A 2014 study classified cases into three types—EBS, JEB and DEB—and reviewed their times of death. The first two types tended to die in infancy and the last in early adulthood. In a survey of 11 families affected by the disease, lack of awareness of the disease by both the public and health care providers raised concerns about the care provided.
Sources: en.wikipedia.org
Mechanism The reaction of tetrazines with trans-cyclooctenes is a highly specific biorthogonal reaction recognized for its rapid reaction rates, compatibility with physiological environments, and its metal-free characteristics. Commonly referred to as tetrazine ligation, the reaction was initially reported in 2008 and has since become a widely adopted bioorthogonal chemistry tool in both in vivo and in vitro studies. The tetrazine ligation is a specific type of inverse electron demand Diels-Alder (shown in the second mechanism in Figure 13) (iEDDA) [4+2] cycloaddition. The mechanism involves an electron-deficient tetrazine, typically a substituted 3,6-diaryl-s-tetrazine functioning as the diene and an electron-rich strained alkene, typically a trans-cyclooctene (TCO) compound, serving as the dienophile (shown in Figure 14). Trans-cyclooctenes have a high strain energy of 17.9 kcal/mol due to their non-planar double bond, making it very reactive and a strong dienophile. Following the initial iEDDA, a retro-Diels-Alder (shown in the last mechanism in Figure 13) reaction occurs, resulting in the expulsion of nitrogen gas (N2), driving the reaction forward. This promotes the irreversible nature of the reaction, which enhances its suitability for bio-labeling applications. This reaction has fast reactivity at low concentrations, with second order rate constants ranging from 1–106 M−1 s−1 depending on the specific tetrazine and TCO pair.
The investigation did not lead to public accusations, and Georgiev himself learned about it years later. In September 1949, Stalin put an end to so-called "people's democracy" in Eastern Europe, beginning the final formation of totalitarian regimes in the region. Those closest to the communists, the Zveno activists, such as Traicho Dobroslavsky, Trifon Trifonov, and Kiril Shterev, demanded a public stand against the disgraced Damyan Velchev, Vasil Yurukov, and Petko Stainov. In a conference held on February 19, 1949, the People's Union Zveno accepted that it had fulfilled its role and decided to dissolve itself and join the Fatherland Front in full. With this act, Zveno ceased to exist as an independent political organization. Georgiev left politics in 1952 and led a reclusive life until his death.
Genetic vaccines are based on the principle of uptake of a nucleic acid into cells, whereupon a protein is produced according to the nucleic acid template. This protein is usually the immunodominant antigen of the pathogen or a surface protein that enables the formation of neutralizing antibodies. The subgroup of genetic vaccines encompass viral vector vaccines, RNA vaccines and DNA vaccines.
== Development == The CPT was originally built for the Tandem Accelerator Superconducting Cyclotron (TASCC) facility at Chalk River Laboratories in Chalk River, Ontario, Canada. However, it was transferred to Argonne National Laboratory when the TASCC accelerator was decommissioned in 1998 due to funding issues. The CPT spectrometer is designed to provide high-precision mass measurements of short-lived isotopes using radio-frequency (RF) fields. Accurate mass measurements of particular isotopes such as selenium-68 are important in the understanding of the detailed reaction mechanisms involved in the rapid-proton capture process, which occurs in astrophysical events like supernovae explosions and X-ray bursts. An X-ray burst is one possible site for the rp-process mechanism which involves the accretion of hydrogen and helium from one star onto the surface of its neutron star binary companion. Mass measurements are required as key inputs to network calculations used to describe this process in terms of the abundances of the nuclides produced, the light-curve profile of the X-ray bursts, and the energy produced. In the current configuration, more than 100 radioactive isotopes have been measured with half-lives much less than a second and with a precision (Δm/m) approaching 10−9. Recently, a novel injection system, the RF gas cooler, has been installed on the CPT to allow fast reaction products to be decelerated, thermalized and bunched for rapid and efficient injection.
Sources: en.wikipedia.org
The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the GIPR gene. GIP-R is a member of the class B family of G protein–coupled receptors. GIP-R is found on beta-cells in the pancreas, where it serves as the receptor for the gastric inhibitory polypeptide (GIP).
In June 1911, while attending a conference in Stettin, Hahn met Edith Junghans (1887–1968), a student at the Royal School of Art in Berlin. They saw each other again in Berlin, and became engaged in November 1912. On 22 March 1913 the couple were married in Stettin, where Edith's father, Paul Ferdinand Junghans, was a high-ranking law officer and President of the City Parliament until his death in 1915. After a honeymoon at Punta San Vigilio on Lake Garda in Italy, they visited Vienna, and then Budapest, where they stayed with George de Hevesy. They had one child, Hanno Hahn, who was born on 9 April 1922. Hanno enlisted in the army in 1942, and served on the Eastern Front in World War II as a panzer commander. He lost an arm in combat. After the war he became an art historian and architectural researcher (at the Hertziana in Rome), known for his discoveries in the early Cistercian architecture of the 12th century. In August 1960, while on a study trip in France, Hanno died in a car accident, together with his wife and assistant Ilse Hahn née Pletz. They left a fourteen-year-old son, Dietrich Hahn. In 1990, the Hanno and Ilse Hahn Prize for outstanding contributions to Italian art history was established in memory of Hanno and Ilse Hahn to support young and talented art historians. It is awarded biennially by the Bibliotheca Hertziana – Max Planck Institute for Art History in Rome.
== Cause == The cause of PAH is unknown. Idiopathic PAH (WHO group 1.1) is not associated with an underlying disease or exposure. It is estimated that 39-46% of those with PAH have the idiopathic variant. Group 1.2 PAH includes the variants that are heritable. Genetic variants or mutations in bone morphogenic protein receptor 2 (BMPR2) account for approximately 75-80% of cases of heritable PAH. BMPR2 mutations are also seen in 20% of idiopathic PAH. BMPR2 is a protein involved in endothelial cell (cells that line blood vessels) proliferation and remodeling. Other types of genes coding for proteins involved in BMPR2 signaling have also been implicated as causes of heritable PAH, such as activin A receptor type-2-like-1 ACVRL1, Endoglin (ENG), SMAD genes encoding for SMAD transcription factors involved in downstream BMPR2 signaling and cell growth including Smad1, Smad4 and Smad9. KCNK3 encodes for a potassium channel which regulates membrane potential across cells thus controlling vascular tone. Eukaryotic translation initiation factor 2 alpha kinase 4 (E1F2AK4) is mutated causes heritable pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Group 1.3 PAH includes disease that is due to drug or toxin exposures. Methamphetamines, the chemotherapeutic dasatinib and the appetite suppressant and diet drug fenfluramine are associated with PAH. Group 1.4 PAH is disease that is associated with underlying disease.
== Awards and distinctions == National Biotechnology Award, (2000) Iranian Academy of Science, Associate member (1992–2008) Iranian Academy of Literature, Associate member (2003–2008) President, Institute of Biophysics and Biochemistry. President, Biomaterial Research Center Chairman, Faculty of Sciences, University of Tehran
Both pyruvate and oxaloacetate are key components of cellular metabolism, contributing as substrates or intermediates in fundamental processes such as glycolysis, gluconeogenesis, and the citric acid cycle. Glutamate also plays an important role in the body's disposal of excess or waste nitrogen. Glutamate undergoes deamination, an oxidative reaction catalysed by glutamate dehydrogenase, as follows:
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.